This article is more than 5 years old. Information may no longer be current.

Keryx submits application for EU approval of hyperphosphatemia treatment in CKD patients

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

New York-based Keryx Biopharmaceuticals Inc. said that it has submitted a Marketing Authorization Application to the European Medicines Agency (EMA), seeking the approval of Zerenex (ferric citrate coordination complex) to treat hyperphosphatemia in patients with chronic kidney disease, including dialysis- and non-dialysis dependent.

EMA approval would provide marketing authorization in all 27 member-states of the European Union, as well as in Norway, Liechtenstein, and Iceland.

(Related: FDA approves new phosphate binder Velphoro for dialysis patients)

The company also has a new drug application for Zerenex under review in the United States. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex in patients with chronic kidney disease on dialysis.

In January, the company's Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co. Ltd. received marketing approval for the drug, branded Riona, in Japan to treat hyperphosphatemia in patients with CKD, including dialysis and non-dialysis dependent.